Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Vote In favor of Your #1 Method for diminishing Pressure - 2High Court freezes government move to shutter Army Radio pending ruling
- 3Thousands of Walgreens nasal spray bottles recalled. See which ones.
- 4Day to day Temporary Positions That Compensate Fairly in the US
- 5Which Startup's Innovation Could Reform Medical care?
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Find the Lively Food Markets of South America
- Parents search for children missing since a volcanic eruption in Colombia 40 years ago
- Nations for Rock Climbing
- Parents who delay baby's first vaccines also likely to skip measles shots
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Find Serenity: 10 Stunning Setting up camp Areas
- The Most Astonishing Arising Advances to Watch
